Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists

E. Bremer, B. ten Cate, D.F. Samplonius, N. Mueller, H. Wajant, A.J. Stel, M.E.D. Chamuleau, A.A. van de Loosdrecht, J. Stieglmaier, G.H. Fey, W. Helfrich

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)597-604
JournalCancer Research
Volume68
Issue number2
DOIs
Publication statusPublished - 2008

Cite this

Bremer, E., ten Cate, B., Samplonius, D. F., Mueller, N., Wajant, H., Stel, A. J., ... Helfrich, W. (2008). Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Research, 68(2), 597-604. https://doi.org/10.1158/0008-5472.CAN-07-5171